Zimmer Biomet (Formerly Known As Biomet Inc.)
56 East Bell Drive
348 articles with Zimmer Biomet (Formerly Known As Biomet Inc.)
Zimmer Biomet Holdings, Inc. announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2018.
Zimmer Biomet Holdings, Inc. announced that it will be participating in the Goldman Sachs 39th Annual Global Healthcare Conference
Zimmer Biomet Holdings, Inc. announced that it will be participating in the Deutsche Bank 43rd Annual Health Care Conference.
Zimmer Biomet Partners with Faith In Practice to Improve Access to Musculoskeletal Care in Guatemala
Zimmer Biomet Holdings, Inc. announced today that it has entered into a partnership agreement with Faith In Practice.
- Net sales of $2.018 billion for the first quarter represent an increase of 2.3% over the prior year period, and a decrease of 1.5% on a constant currency basis - Diluted EPS for the first quarter were $0.85 reported, a decrease of 42.2% from the prior year period - Adjusted diluted EPS for the first quarter were $1.91, a decrease of 10.3% from the prior year period - The Company provides full-year 2018 financial guidance
Zimmer Biomet Holdings, Inc. announced an agreement with Oregon Surgical Institute.
Zimmer Biomet Announces FDA Clearance of the Comprehensive® Augmented Baseplate for Shoulder Reconstruction
Zimmer Biomet Holdings, Inc. announced the completion of the first surgical case utilizing its Comprehensive® Augmented Baseplate, which received FDA clearance on January 3, 2018.
Zimmer Biomet Holdings Inc. announced that it has priced an offering of $450 million principal amount of its floating rate senior unsecured notes due 2021 and $300 million principal amount of its 3.700% senior unsecured notes due 2023.
The FDA laid out eight observations it determined needed correction at the facility.
The Company reported fourth quarter net sales of $2.074 billion.
Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2017 Results
A news release detailing the quarterly and full-year results will be made available at 7 a.m. Eastern Time the morning of the conference call.
The Sidus system will be available in the United States beginning in the First Quarter of 2018.
The pilot study enrolled 46 patients with unilateral, mild-to-moderate, symptomatic knee OA pain from the four trial sites across Europe.
The lawsuit, filed in the U.S. District Court for Eastern Pennsylvania, alleges that Mario Schackelman jumped ship for Zimmer Biomet on Oct. 31 after a decade of selling for Synthes despite clauses in his contract barring him for working for a competitor for two years.
The lawsuit filed by Margo Polett claimed that she re-injured her knees while making a Zimmer promotional video, after a double knee replacement procedure in 2006 using the company's Gender Solutions device.
Zimmer Biomet announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2017.
Zimmer Biomet today announced that Bryan C. Hanson has been appointed President and CEO and a member of the Board of Directors, effective today.
Diluted earnings per share for the quarter were $0.48, a decrease of 38.5% from the prior year period.
Zimmer Biomet today announced the official launch of its Vitality+ and Vital Spinal Fixation Systems in the United States at the 2017 NASS Annual Meeting.